These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26771153)

  • 1. Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies.
    Patti G; Ricottini E; De Luca L; Cavallari I
    J Cardiovasc Pharmacol; 2016 Apr; 67(4):336-43. PubMed ID: 26771153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang A; Lella LK; Brener SJ
    Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel.
    Mizrahi E; Suryadevara RS; Barn K; Boga G; Akram MM; Ismail-Sayed I; Henry YM; Troup MA; Berger PB
    J Invasive Cardiol; 2015 Dec; 27(12):543-6. PubMed ID: 26378415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
    Valenti R; Marcucci R; Comito V; Marrani M; Cantini G; Migliorini A; Parodi G; Gensini GF; Abbate R; Antoniucci D
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1563-70. PubMed ID: 26386764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
    Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
    Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
    Bundhun PK; Huang F
    BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention.
    Federspiel JJ; Anstrom KJ; Xian Y; McCoy LA; Effron MB; Faries DE; Zettler M; Mauri L; Yeh RW; Peterson ED; Wang TY;
    JAMA Cardiol; 2016 Sep; 1(6):655-65. PubMed ID: 27438179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
    Verdoia M; Barbieri L; Suryapranata H; De Luca G
    Platelets; 2016; 27(2):93-104. PubMed ID: 25970631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Steiner S; Moertl D; Chen L; Coyle D; Wells GA
    Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
    Bagai A; Peterson ED; Honeycutt E; Effron MB; Cohen DJ; Goodman SG; Anstrom KJ; Gupta A; Messenger JC; Wang TY
    Eur Heart J Acute Cardiovasc Care; 2015 Dec; 4(6):499-508. PubMed ID: 25515725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Switching from clopidogrel to prasugrel: Efficacy and safety data].
    Yamaç AH; Göktekin O
    Turk Kardiyol Dern Ars; 2015 Oct; 43 Suppl 2():20-4. PubMed ID: 27326447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
    Hong J; Turgeon RD; Pearson GJ
    Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
    Curr Med Res Opin; 2014 Jan; 30(1):37-49. PubMed ID: 24083626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis.
    Wongsalap Y; Ungsriwong S; Kumtep W; Saokaew S; Senthong V; Kengkla K
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):991-1000. PubMed ID: 34169380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.